ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients
Portfolio Pulse from
ARS Pharmaceuticals' neffy® (Epinephrine Nasal Spray) has been added to the national formularies of OptumRx, Cigna Healthcare, and Navitus Health Systems, expanding its coverage to half of all patients managing Type 1 allergic reactions. This brings the total number of formulary platforms covering neffy to 30.
February 21, 2025 | 12:15 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cigna Healthcare has added ARS Pharmaceuticals' neffy® to its national formulary, expanding access for patients managing Type 1 allergic reactions.
The inclusion of neffy® in Cigna's formulary is a positive development, potentially increasing customer satisfaction and retention by offering more treatment options. This could lead to a positive short-term impact on Cigna's stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80